China smartphone shipments slumped in June on inventory overhang: Jefferies
Calafiore Massimo, President and CEO of Orthofix Medical (TASE:BLWV) Inc. (NASDAQ:OFIX), recently acquired 9,914 shares of the company’s common stock. The purchase, completed on March 5, 2025, was executed at a weighted average price of $17.43 per share, with a price range between $17.265 and $17.595. The total transaction amounted to approximately $172,801. The medical device company, with a market capitalization of $658 million, maintains strong liquidity with a current ratio of 2.57. Following this acquisition, Massimo now holds 222,404 shares of Orthofix Medical, including previously reported restricted stock units. According to InvestingPro analysis, the stock appears undervalued, with analyst price targets ranging from $22 to $27.20 per share. Get access to more detailed insights and 6 additional ProTips for OFIX through InvestingPro’s comprehensive research reports.
In other recent news, Orthofix International reported fourth-quarter earnings with revenue reaching $215.7 million, a 7.6% increase from the previous year, surpassing the consensus estimate of $212.7 million. The company’s adjusted EBITDA also exceeded expectations at $23.9 million, driven by strong performance in its Global Orthopedics segment and BioStim. However, Orthofix’s revenue guidance for fiscal year 2025, set between $818 million and $826 million, fell short of analysts’ projections due to the discontinuation of certain product lines. Despite this, Orthofix expects adjusted EBITDA for FY25 to range between $82 million and $86 million, with a focus on profitable growth. BTIG maintained a Neutral rating on Orthofix, noting potential challenges in the first quarter of FY25 and a moderate growth trajectory. Meanwhile, Canaccord Genuity initiated coverage with a Buy rating and a $24 price target, expressing optimism about Orthofix’s integration efforts following its merger with SeaSpine. The firm highlighted Orthofix’s strategic focus on innovation and margin expansion, viewing the current stock valuation as attractive.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.